Effect of BCG Revaccination on Occupationally Exposed Medical Personnel Vaccinated against SARS-CoV-2
Por:
Ramos-Martinez, Espiridion, Falfan-Valencia, Ramces, Perez-Rubio, Gloria, Andrade, Warrison Athanasio, Rojas-Serrano, Jorge, Ambrocio-Ortiz, Enrique, Galicia-alvarez, Dennisse S., Barcenas-Montiel, Isaac, Velasco-Medina, Andrea, Velazquez-Samano, Guillermo
Publicada:
1 nov 2021
Categoría:
Biochemistry, genetics and molecular biology (miscellaneous)
Resumen:
The production of specific neutralizing antibodies by individuals is
thought to be the best option for reducing the number of patients with
severe COVID-19, which is the reason why multiple vaccines are currently
being administered worldwide. We aimed to explore the effect of
revaccination with BCG, on the response to a subsequent anti-SARS-CoV-2
vaccine, in persons occupationally exposed to COVID-19 patients. Two
groups of 30 randomized participants were selected: one group received a
BCG revaccination, and the other group received a placebo. Subsequently,
both groups were vaccinated against SARS-CoV-2. After each round of
vaccination, the serum concentration of Th1/Th2 cytokines was
determined. At the end of the protocol, neutralizing antibodies were
determined and the HLA-DRB loci were genotyped. The participants from
the BCG group and anti-SARS-CoV-2 vaccine group had increased serum
cytokine concentrations (i.e., IL-1 beta, IL-4, IL-6, IL-12p70, IL-13,
IL-18, GM-CSF, INF-gamma, and TNF-alpha) and higher neutralizing
antibody titers, compared to the group with Placebo-anti-SARS-CoV-2.
Twelve HLA-DRB1 alleles were identified in the Placebo-anti-SARS-CoV-2
group, and only nine in the group revaccinated with BCG. The DRB1*04
allele exhibited increased frequency in the Placebo-anti-SARS-CoV-2
group; however, no confounding effects were found with this allele. We
conclude that revaccination with BCG synergizes with subsequent
vaccination against SARS-CoV-2 in occupationally exposed personnel.
Filiaciones:
Ramos-Martinez, Espiridion:
Unidad de Investigación en Medicina Experimental, Facultad de Medicina, Universidad Nacional Autónoma de México, Ciudad de México, 06720, Mexico
Falfan-Valencia, Ramces:
HLA Laboratory, Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas, Mexico City, 14080, Mexico
Perez-Rubio, Gloria:
HLA Laboratory, Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas, Mexico City, 14080, Mexico
Andrade, Warrison Athanasio:
Departamento de Biologia Celular e Molecular e Bioagentes Patogênicos, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto SP, 14049-900, Brazil
Rojas-Serrano, Jorge:
Unidad de enfermedades del Intersticio Pulmonar y Reumatología, Instituto Nacional de Enfermedades Respiratorias, “Ismael Cosío Villegas”, Ciudad de México, 14080, Mexico
Ambrocio-Ortiz, Enrique:
HLA Laboratory, Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas, Mexico City, 14080, Mexico
Galicia-alvarez, Dennisse S.:
Servicio de Alergia e Inmunología Clínica, Hospital General de México, “Dr. Eduardo Liceaga”, Mexico City, 06720, Mexico
Barcenas-Montiel, Isaac:
Servicio de Alergia e Inmunología Clínica, Hospital General de México, “Dr. Eduardo Liceaga”, Mexico City, 06720, Mexico
Velasco-Medina, Andrea:
Servicio de Alergia e Inmunología Clínica, Hospital General de México, “Dr. Eduardo Liceaga”, Mexico City, 06720, Mexico
Velazquez-Samano, Guillermo:
Servicio de Alergia e Inmunología Clínica, Hospital General de México, “Dr. Eduardo Liceaga”, Mexico City, 06720, Mexico
gold, Gold
|